The potential of XPO1 inhibitors as a game changer in relapsed/refractory hematologic malignancies
XPO1 is a transporter receptor protein that transports leucine-rich proteins from the nucleus into the cytoplasm through the nuclear pore complex. In hematologic malignancies, XPO1 is often overexpressed, leading to abnormal regulation of cell growth and apoptosis or abnormal cell cycle regulation. Therefore, XPO1 inhibitors can be used as targeted drugs to block the transport of overexpressed XPO1, thus treating hematologic malignancies. We summarized the use of XPO1 inhibitors in clinical studies according to different hematologic malignancies and reviewed their efficacy and toxicity.
Keywords: XPO1 inhibitor, hematologic malignancies, selinexor, targeted therapy